CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Biotech co Alector rises after premium-priced $75 mln stock sale

By Reuters News

** Biotech firm Alector's ALEC.O shares up 6.8% at $2.04 before the bell on Fri after $75 mln follow-on priced

** ALEC sells 36.6 mln shares at $2.05, 7.3% above their last sale on Thurs

** Financing includes participation from new and existing investors, including TCGX, BVF Partners, among others, co says

** It intends to use net offering proceeds for general purposes, including R&D, working capital, capex, expenses, potential acquisitions

** Morgan Stanley and BTIG joint bookrunners

** On Oct 5, ALEC's stock ultimately finished session up ~10% at $1.99 after it announced that Genentech, a unit of Swiss drugmaker Roche ROPC.S, will pay up to $1.27 bln to license AL050, ALEC's experimental drug for Parkinson's disease

** South San Francisco, California-based ALEC has ~111.7 mln shares outstanding

** At Thurs close, stock up 30% over the past three months

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk